Open access – Page 28

Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leukemia (B-ALL…

Correction: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

16 de October de 2024 by Journal for ImmunoTherapy of Cancer current issue

Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events

12 de October de 2024 by Rubin, L., Talmon, A., Ribak, Y., Lavie, D., Nechushtan, H., Caplan, N., Lotem, M., Shamriz, O., Adini, I., Tal, Y.

Given the broad implementation of immune checkpoint inhibitors (ICI) for cancer therapy, we encounter a variety of immune-related adverse events (irAE) including immune-related blood eosinophilia. Eosinophilia demonstrated a potential positive predict…

Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy

26 de September de 2024 by Wu, X., You, J., Zhang, S., Zhang, B.